Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition

CYP2U1: a cardiac metabolic switch alleviating obesity cardiomyopathy via lipid metabolic reprogramming.

Jing Chen Zhong-Xi Chen Yu-Bin Lan Rong Fang Jing-Jing Xie Jiang-Shun Yang Xiao-Dan Zhang Sui-Lin Jia Guo-Yong Huang
Oct 2026 · Molecular and Cellular Biochemistry · 0 citations · 48 references
Medicine

TL;DR

Cardiac-specific overexpression of CYP2U1 safeguards against high-fat diet (HFD)-induced myocardial dysfunction and limits obesity-driven cardiac inflammation by coupling suppression of the NF-κB/C/EBPβ-IL-6 axis with a shift in lipid mediators toward DHA-derived specialized pro-resolving mediators.

DOI PubMed Semantic Scholar
View source

Similar papers

Open access Oct 2026

NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis

Diabetic cardiomyopathy (DCM) is a serious cardiac complication of diabetes, characterized by myocardial metabolic dysregulation, mitochondrial dysfunction, and structural remodeling. Disruption of circadian clock genes has been implicated in metabolic diseases, yet the role of neuronal PAS domain protein 2 (NPAS2)...

Wen-Jiao Li, Bin Han, Di-Kun Zhu et al. · 0 citations
Open access Sep 2026

Sestrin2 mitigates obesity-associated HFpEF via adaptive IRE1α-XBP1 signaling and redox regulation.

It is demonstrated that Sestrin2 has cardioprotective effects on obesity-associated HFpEF and is associated with the activation of adaptive IRE1α-XBP1 signaling involving Sigmar1, together with improved metabolic and redox homeostasis.

Ke-Xin Zhang, Cheng-Xia Kan, Jing-Wen Zhang et al. · 0 citations
Open access Sep 2026

NPAS2 promotes MASLD and hepatocarcinogenesis through SIRT1-mediated PPARγ suppression

Emerging evidence links circadian disruption to metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying mechanisms remain elusive. NPAS2, a core circadian regulator, has an undefined role in the pathogenesis of MASLD and its progression to hepatocellular carcinoma (HCC). This study aime...

Jiao Mu, Jia-Li Ye, Jia-Hao Zhang et al. · 0 citations
Sep 2026

Trimethylamine N-oxide drives cardiac hypertrophy through H3K27ac-mediated enhancer activation of ketohexokinase.

Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, promotes cardiac hypertrophy, yet the molecular mechanisms linking microbial metabolism to cardiac gene expression remain incompletely defined. Ketohexokinase (KHK), the rate-limiting enzyme of fructose catabolism, is implicated in cardiac pathology, b...

Ping Li, Yuan Liu, Gui-Ling Xiong et al. · 0 citations
Oct 2026

QHHP Ameliorates MASH Through Modulation of a Cyp4a32-PPARγ-CD36-Associated Lipotoxic Axis.

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive stage of metabolic dysfunction-associated fatty liver disease, for which effective pharmacological therapies remain limited. Qinggan Huatan Huoxue Prescription (QHHP) has been used clinically in the management of fatty liver disease and related me...

Fei-Xiang Xiong, Feng-Na Yan, Yu-Yong Jiang et al. · 0 citations
Oct 2026

Veratric acid ameliorates metabolic-dysfunction-associated fatty liver disease via targeting PPARG.

Investigation of the protective effects and underlying mechanisms of VA in a high-fat diet induced mouse model of MAFLD demonstrated that VA significantly alleviated HFD-induced weight gain, adipose tissue accumulation, and hepatic steatosis, and suggested its potential as a natural therapeutic agent for MAFLD.

Si-Qi Liu, Ting-Li Pan, Qiu-Chen Cheng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.